Armolipid-L

Armolipid-L is a branded nutraceutical **combination dietary supplement** formulated to support the reduction and control of blood lipids, specifically cholesterol and triglycerides, to reduce cardiovascular risk. Its primary active ingredients typically include **red yeast rice (Monascus purpureus, source of monacolins/statin analogues such as monacolin K), berberine (Berberis aristata extract), policosanol, folic acid, coenzyme Q10, and astaxanthin**. These ingredients act synergistically to lower LDL cholesterol, total cholesterol, and triglycerides, with effects attributed to: inhibition of endogenous cholesterol synthesis (via HMG-CoA reductase inhibition by monacolins), upregulation of hepatic LDL receptor activity (by berberine), antioxidant activity (coenzyme Q10, astaxanthin), and homocysteine reduction (folic acid). Armolipid-L is typically intended for use in conjunction with a balanced diet and lifestyle modifications, particularly in individuals with mild to moderate hypercholesterolemia, metabolic syndrome, or statin intolerance. It is developed and marketed by companies such as Mylan and Rottapharm Madaus (part of Viatris group)[1][2][3][5][6][7].

Brand names

Armolipid-L